New CEO, FDA filing progress, but Elevidys safety overhang persists
New CEO brings turnaround credibility Sarepta named Michael Severino, a veteran biopharma executive, as CEO effective July 28, 2026, and granted him equity awards tied to a $17.74 exercise price. A fresh leader with a strong track record can improve execution and restore investor confidence, though the impact will take time to show.
Leadership change is a major new event that can drive future value and investor sentiment.
FDA accepts applications to convert two DMD drugs to full approval The FDA accepted Sarepta's applications to convert accelerated approvals for AMONDYS 45 and VYONDYS 53 to traditional approvals, with a decision due February 2027. Success would strengthen the company's non-gene-therapy DMD franchise and reduce reliance on Elevidys, a key positive.
This regulatory step could diversify revenue and lower concentration risk around Elevidys.
Elevidys sales collapse and safety restrictions remain Q2 revenue fell 34% as Elevidys sales dropped 65% to $98.1 million due to a shipment suspension for non-ambulatory patients. The FDA still restricts Elevidys to ambulatory patients and requires a boxed warning for fatal liver injury; new two-year data do not remove these limits, keeping a cloud over the key product.
Elevidys is central to Sarepta's prospects, and its safety issues and sales decline are the main drag on the stock.
High short interest and low valuation reflect deep skepticism Short interest stands at 28.86% of the float, and the stock trades at about 0.9 times trailing sales versus 3.2 times for a rare-disease peer. While a low valuation can attract bargain hunters, heavy shorting signals that many investors doubt the company's ability to overcome Elevidys setbacks.
Short interest and valuation show how the market is pricing the risks and can amplify volatility.